TARA logo

Protara Therapeutics, Inc. Common Stock


TARA: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Show TARA Financials

Consumer Interest
SEC Filings

Recent trades of TARA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by TARA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Sterile aqueous choline salt compositions Apr. 26, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of TARA in WallStreetBets Daily Discussion


Recent insights relating to TARA

CNBC Recommendations

Recent picks made for TARA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TARA

Corporate Flights

Flights by private jets registered to TARA